Literature DB >> 8948274

Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course.

T J Marrie1, R W Peeling, M J Fine, D E Singer, C M Coley, W N Kapoor.   

Abstract

OBJECTIVES: To determine the etiology of community-acquired pneumonia in patients treated in an ambulatory setting, using serological methods, and to compare presenting symptoms, radiographic manifestations, and clinical outcomes of patients with pneumonia of "atypical" and undetermined etiology. PATIENTS AND METHODS: This prospective cohort study was conducted in emergency room and outpatient facilities of Victoria General Hospital, Halifax, Nova Scotia, and in offices of participating family doctors based in Halifax. One hundred forty-nine adults with acute onset of one or more symptoms or signs suggestive of pneumonia and radiographic evidence of pneumonia who provided informed consent were enrolled. Patients known to be HIV positive or who had been discharged from a hospital within the previous 10 days were ineligible for enrollment. Demographic features and clinical data were collected by direct patient interview and chart review by trained research nurses. Outcome measures included quantitative evaluation of pneumonia-specific symptoms, and responses to the Short Form 36 Health Survey at presentation and at 30 days after presentation. Information was also collected on each patient's health prior to pneumonia, as well as the time until each patient's self-reported return to work and to usual activities. The etiology of pneumonia was determined by testing acute and convalescent serum samples for antibodies to Legionella pneumophila serogroup 1, Mycoplasma pneumoniae, Chlamydia pneumoniae, Chlamydia psittaci, Coxiella burnetii, adenovirus, respiratory syncytia virus, influenza viruses A and B, and parainfluenza viruses 1, 2, 3.
RESULTS: The study population consisted of 149 patients, 54 (36%) of whom were men, with a mean age (+/- SD) of 41 +/- 15 years. An etiological diagnosis was made in 74 (49.7%) patients using serological methods. Etiological agents included M pneumoniae 34 (22.8%); C pneumoniae 16 (10.7%); M pneumoniae and C pneumoniae 5 (3.4%); C burnetii 4 (2.7%); influenza A virus 4 (2.7%); and other agents 6% (7.4%). Three patients (2%) had a conventional bacterial etiology, and 72 patients (48.3%) had pneumonia of undetermined etiology. Patients with pneumonia of known (atypical) and undetermined etiology were similar in terms of age, gender, race, education, employment, and comorbidity. Despite a higher proportion of patients with pneumonia of known etiology reporting sweats, chills, and headache at presentation, the two groups were similar for symptom severity and bother. The patients with pneumonia of undetermined etiology were more likely to have multilobar pneumonia (P < 0.02). Both patients with atypical pneumonia and those with pneumonia of undetermined etiology suffered severe deterioration of physical functioning with a marked but incomplete recovery at 30 days. Those with atypical pneumonia had higher physical functioning and general mental health scores at 30 days.
CONCLUSIONS: Nearly half the cases of ambulatory community-acquired pneumonia are due to "atypical" agents. It is not possible to reliably distinguish patients with atypical pneumonia from those with pneumonia of undetermined etiology by clinical features at baseline. The outcomes in terms of resolution of symptoms, functional status, return to work, and return to usual activities are essentially similar in the two groups.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8948274     DOI: 10.1016/s0002-9343(96)00255-0

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  49 in total

1.  Providing better care for patients who may have pneumonia.

Authors:  W F Holmes; M Woodhead
Journal:  Thorax       Date:  1999-10       Impact factor: 9.139

2.  BTS Guidelines for the Management of Community Acquired Pneumonia in Adults.

Authors: 
Journal:  Thorax       Date:  2001-12       Impact factor: 9.139

Review 3.  Pneumonia and pregnancy.

Authors:  W S Lim; J T Macfarlane; C L Colthorpe
Journal:  Thorax       Date:  2001-05       Impact factor: 9.139

4.  Community-Acquired Pneumonia: An Overview.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-04       Impact factor: 3.725

5.  Ambulatory community-acquired pneumonia: the predominance of atypical pathogens.

Authors:  B A Cunha
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-10       Impact factor: 3.267

6.  Guidelines for the management of adult lower respiratory tract infections--full version.

Authors:  M Woodhead; F Blasi; S Ewig; J Garau; G Huchon; M Ieven; A Ortqvist; T Schaberg; A Torres; G van der Heijden; R Read; T J M Verheij
Journal:  Clin Microbiol Infect       Date:  2011-11       Impact factor: 8.067

7.  Community epidemiology of Chlamydia and Mycoplasma pneumoniae in LRTI in France over 29 months.

Authors:  Jacques Gaillat; Antoine Flahault; Bertille deBarbeyrac; Jeanne Orfila; Henri Portier; Jean-Pierre Ducroix; Christiane Bébéar; Charles Mayaud
Journal:  Eur J Epidemiol       Date:  2005       Impact factor: 8.082

8.  Acute intrahepatic cholestasis accompanied with Chlamydophila pneumoniae infection.

Authors:  Megumi Toyoda-Akui; Hiroaki Yokomori; Fumihiko Kaneko; Yuki Shimizu; Hajime Takeuchi; Kumiko Tahara; Hide Yoshida; Hirobumi Kondo; Tadashi Motoori; Makoto Ohbu; Masaya Oda; Toshifumi Hibi
Journal:  Med Mol Morphol       Date:  2011-03-23       Impact factor: 2.309

9.  Chlamydia pneumoniae replicates in Kupffer cells in mouse model of liver infection.

Authors:  Antonella Marangoni; Manuela Donati; Francesca Cavrini; Rita Aldini; Silvia Accardo; Vittorio Sambri; Marco Montagnani; Roberto Cevenini
Journal:  World J Gastroenterol       Date:  2006-10-28       Impact factor: 5.742

10.  Contributions of symptoms, signs, erythrocyte sedimentation rate, and C-reactive protein to a diagnosis of pneumonia in acute lower respiratory tract infection.

Authors:  R M Hopstaken; J W Muris; J A Knottnerus; A D Kester; P E Rinkens; G J Dinant
Journal:  Br J Gen Pract       Date:  2003-05       Impact factor: 5.386

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.